In myocardial excitation, the delay between the excitation of the atria and ventricles is determined by the sum of atrial and atrioventricular nodal conduction. This delay, measured in milliseconds, is reflected on the standard 12-lead electrocardiogram (ECG) by the PR interval or PQ interval. The PR interval has a substantial heritable component, with heritability estimates ranging between 30 and 50% ([@R1],[@R2],[@R3],[@R4]).

Atrial fibrillation (AF) is the most common sustained arrhythmia and is independently associated with increased risk of stroke, heart failure, dementia, and death ([@R5]). AF prevalence increases markedly with age, to nearly 9% in those 80-89 years of age, and is estimated to triple by the year 2050. ([@R6]). Common genetic risk factors for AF ([@R7]) include variants on chromosome 4q25 near the *PITX2* gene ([@R8]), in 16q22.3 near the *ZFHX3* (*ATBF1*) gene ([@R9]), in 1q21 in the *KCNN3* gene ([@R10]) and the K897T variant in the *KCNH2* gene on 7q36.1 ([@R11]).

The PR interval is an intermediate phenotype for AF, as alterations in atrial action potential duration and in atrioventricular conduction influence both PR interval and AF risk ([@R12]). Longitudinal data from the Framingham Heart Study (FHS) and the Atherosclerosis Risk in Communities Study (ARIC) demonstrate that PR interval prolongation is a predictor of increased AF risk ([@R13], [@R14]). In addition, PR interval prolongation has been shown in FHS to be an independent predictor in a multifactorial risk score for AF predisposition ([@R15]).

We undertook a meta-analysis of GWAS to investigate the genetic determinants of the PR interval and their relationship to AF risk. Our goal was to identify genes that can provide insights into atrial disease and lead to novel opportunities for AF prevention and therapy.

We studied individuals of European descent from seven community based studies: the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES) ([@R16]), ARIC ([@R17]), the Cardiovascular Health Study (CHS) ([@R18]), FHS ([@R19]), the Kooperative Gesundheitsforschung in der Region Augsburg Study (KORA) ([@R20]), the Rotterdam Study (RS) ([@R21]), and the SardiNIA study ([@R3]) ([Table 1](#T1){ref-type="table"} and [Online Methods](#SD1){ref-type="supplementary-material"}). Phenotypic data including resting 12-lead electrocardiography, height, weight, systolic blood pressure, and medication use were collected using standardized protocols in all studies. Exclusion criteria and covariates are described in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Study participants were genotyped using a variety of genome-wide SNP arrays. To facilitate comparison of results across studies, we imputed to the 2.5 million HapMap SNPs ([@R22]). A recent review supports the validity of combining results across statistical and genotyping platforms ([@R23]). Genotyping details, SNP quality control filters, and imputation methods for each study are summarized in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

After exclusions, 28,517 individuals were available for study. The association of each SNP with the PR interval was adjusted for age, sex, RR interval, height, body mass index (BMI), systolic blood pressure, and study site in studies with multiple recruitment sites. Studies adjusted for or excluded individuals using drugs known to alter the PR interval including beta-blockers, diuretics and non-dihydropyridine calcium antagonists.

Due to restrictions imposed by Institutional Review Boards at several of the study sites on the sharing of individual genetic data, it was not possible to perform analyses based on combined individual-level data. Therefore, we conducted inverse variance-weighted fixed-effects meta-analysis of the beta estimates from linear regression of PR interval. The coefficients, generated for each SNP, estimate the difference in PR interval per additional copy of the minor allele, adjusted for the covariates in the model. The genome-wide significance threshold was 5×10^-8^.

To determine if there was an association between the PR-associated loci and AF risk, we meta-analyzed results from 4 studies of AF in subjects of European descent. The first was a meta-analytic study of 896 prevalent AF cases and 15,768 referents from the CHARGE cohorts ([@R9]). The second was a meta-analytic study of 2,517 incident AF cases and 21,337 referents from the CHARGE cohorts. The third and fourth were independent case-control studies of prevalent AF: the German Competence Network on Atrial Fibrillation (AFNET, 2,145 cases and 4,073 controls) ([@R10]); and the Cleveland Clinic AF study (CCAF, 183 cases and 164 controls) ([@R24]) ([Table 3](#T3){ref-type="table"} and [Online Methods](#SD1){ref-type="supplementary-material"}). We performed an inverse-variance weighted meta-analysis of the logistic-regression results from the prevalent AF studies and the proportional hazards results from the incident AF study. The Bonferroni adjusted significance threshold was *P* = 0.05/9 = 0.0056.

The study was performed in accordance with the Helsinki declarations and was approved by the local medical ethics and institutional review boards. All participants gave signed informed consent to use their DNA for genetic analyses.

The distribution of results from the meta-analysis of PR GWAS is summarized in [Figure 1](#F1){ref-type="fig"}. The Q-Q plot in [Figure 2](#F2){ref-type="fig"} shows a clear excess of extreme p-values. Overall, nine loci showed independent association signals with *P*\<5×10^-8^. We determined the genomic control factor (λ) for the linear regression analysis of PR interval to be 1.076 and report overall analysis results unadjusted for this λ value ([@R25]). We did not observe evidence of heterogeneity in effect sizes for any of the nine loci (I^2^-statistic, all p\>0.05, [Table 2](#T2){ref-type="table"}).

The strongest genome-wide association signal for PR interval was in chromosomal region 3p22.2. In this region we detected two association signals, one covering *SCN10A* (rs6800541, *P* = 2.1×10^-74^) and the other *SCN5A* (rs11708996, *P* = 6.0×10^-26^) ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). These variants are in low LD (r^2^ = 0.031). In a meta-analysis of linear regression results from models including both SNPs, these SNPs remained independently associated with PR interval (rs6800541, *P*= 9.7×10^-82^; rs11708996, *P* = 1.1×10^-33^), suggesting they represent independent association signals.

*SCN10A* encodes the voltage gated sodium channel Nav1.8, essential for cold perception in afferent nociceptive fibers of sensory dorsal root ganglia ([@R26]). Nav1.8 is expressed in the peripheral sensory nervous system but has not been identified in the heart ([@R27]). In *SCN10A*, two common nonsynonymous SNPs are in high to moderate linkage disequilibrium with the sentinel SNP: rs6795970 (V1073A, r^2^=0.933) and rs12632942 (L1092P, r^2^=0.220) making both SNPs good candidates to mechanistically explain the strongest PR interval association identified in the human genome.

The neighboring *SCN5A* gene encodes Nav1.5, the major cardiac sodium channel, with mutations resulting in Brugada Syndrome, long-QT Syndrome, dilated cardiomyopathy, cardiac conduction disease, idiopathic ventricular fibrillation and AF ([@R28]). *SCN5A* sentinel SNP rs11708996 is in weak LD with rs1805124 (H558R, r^2^=0.034) as well as with two non-coding variants, rs12053903 (r^2^=0.030) and rs11129795 (r^2^=0.058), recently reported to be associated with QT interval ([@R29], [@R30]). This suggests that the PR interval and QT interval modifying effects are distinct.

Six PR interval associations were identified in or near genes involved in human cardiac development ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). *NKX2-5* (rs251253 *P*= 9.5×10^-13^) is the homolog of the Drosophila *tinman* gene and encodes the cardiac specific homeobox transcription factor Nkx2.5 (Csx). Mutations can cause atrium septum defect (ASD) with conduction defects (OMIM \#108900), tetralogy of Fallot (OMIM \#187500), and high degree AV block ([@R31]). In the *NKX2-5* gene region the association extends over 200Kb and includes three other genes *BNIP1*, *C5orf41*, and *ATP6V0E1*. The signal at the *TBX5/TBX3* locus is 230kb downstream of the paralog *TBX5* and *TBX3* genes (rs1896312, *P*= 3.1×10^-17^). Both encode T-box containing transcription factors important for cardiac conduction system formation in the developing heart ([@R32]). *TBX5* is required for the patterning and maturation of the murine atrioventricular and bundle branch conduction system ([@R33]). Deletion of *TBX5* results in longer PR intervals in mice ([@R34]). Mutations are seen in Holt-Oram syndrome (OMIM \#142900) with atrial and ventricular septal defects, conduction disease, and occasionally AF ([@R35]). *TBX3* controls formation of the sinus node and imposes pacemaker function on atrial cells ([@R36]). Mutations cause ulnar-mammary syndrome (OMIM \#181450) with limb, mammary, tooth, genital and cardiac abnormalities ([@R37]).

The *CAV1* and *CAV2* genes (rs3807989, *P* = 3.7×10^-28^) encode caveolins necessary for the development of caveolae involved in signal transduction ([@R38]). *CAV1* is expressed in atrial myocytes. Mice deficient in Cav1 develop dilated cardiomyopathy and pulmonary hypertension ([@R39]). *SOX5* (rs11047543, *P* = 3.3×10^-13^) and the nearby *C12orf67* encode transcription factors. *SOX5* knockout mice die with heart failure marked by hepatic congestion and peripheral edema ([@R40]). *MEIS1* (rs11897119, *P* = 4.6×10^-11^) encodes a homeobox transcription factor implicated in cardiac, hematopoietic and neural development. *MEIS1* deficient mice have malformed cardiac outflow tracts with overriding aorta and ventricular septal defect ([@R41]).

*WNT11* (rs4944092, *P* = 3.2×10^-8^) encodes a signaling protein inducing cardiogenesis in Xenopus and in mice by noncanonical WNT signaling ([@R42]). The nearest gene to a signal on chromosome 4 (rs7692808, *P* = 6.0×10^-20^) is *ARHGAP24*, which encodes a Rho-GTPase-activating protein and key angiogenic regulator involved in cell polarity, cell morphology, and cytoskeletal organisation ([@R43]), but without known relevance to the heart.

Of the nine identified PR loci, five were associated with AF risk (p\<0.0056). These were at *SCN10A* (rs6800541, P=1.5 × 10^-4^) and *SCN5A* (rs11708996, P=7.0 × 10^-4^), as well as at three regions harboring developmental genes, *NKX2-5* (P=2.3 × 10^-3^), *CAV1/CAV2* (P=2.2 × 10^-5^), and *SOX5* (P=2.1 × 10^-4^). In all instances the minor alleles were associated with a decrease in AF risk, irrespective of the direction of their association with PR interval ([Table 4](#T4){ref-type="table"}). Protective ratios against AF were between 0.93 and 0.88 for the minor alleles.

The observation that SNPs associated with both PR interval and AF risk did not exhibit consistent directions of effect may initially seem counterintuitive. However, PR interval is an amalgamated measure of atrial and atrioventricular nodal conduction, which independently affect AF risk. PR intervals at both high and low extremes may be associated with an increase in AF risk. Indeed, existing data from humans and animal models suggest that the effects of genetic variants on atrial repolarization and action potential duration, and their relationship with atrial arrhythmias, are complex ([@R11]). In analogy to the QT interval duration, where both long and short QT intervals are associated with increased ventricular tachycardia risk, assuming a linear association model for AF with PR interval and its underlying genetic variants may not capture the complexity of these relations.

Our study was subject to a number of potential limitations. False positive associations from multiple testing is a limitation of any GWAS, so we used a well-accepted genome-wide association significance threshold equivalent to a Bonferroni correction for 1 million independent tests to reduce false positive findings ([@R44]). Population stratification is also a concern, so we only included study subjects of European descent. The low genomic control inflation factor suggested there was no strong influence of population stratification on our results.

Our study also did not examine patterns of haplotype association. Thus complex haplotype associations may not have been captured. However, genome-wide meta-analysis of haplotypes is currently not feasible, and, in common with other GWAS, our use of imputation to the HapMap leverages available linkage disequilibrium information.

The identification of *SCN10A* was unexpected, as Nav1.8 was previously not thought to play a role in cardiac electrophysiology. In addition, *SCN10A* was the only locus where two common nonsynonymous variants were in high LD with a sentinel SNP and thus are likely causal candidates. The second key finding was that the majority of association signals we identified were in cardiac developmental genes including two, *NKX2-5* and *TBX5*, in which mutations are known to cause well-defined cardiac malformations involving the atrial septum and the atrioventricular junction. The biological mechanisms by which the identified variants influence PR interval and AF remain speculative, and detailed functional investigation will be required to determine the potential contribution of each genomic region.
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###### 

Characteristics of participants in the seven community cohorts included in the meta-analysis of genome-wide association studies of PR. Exclusion criteria is given in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. "Participants after exclusion with genome-wide genotypes available" gives the N used in the analysis. Standard deviation (SD) of PR interval is given after adjustment for all covariates. ^*f*^Samples are from the three generations of the Framingham Heart Study (G1=685, G2=3178, G3=3773).

                                                                              AGES            ARIC            CHS             FHS             KORA F3         KORA S4         Rotterdam       SardiNIA
  --------------------------------------------------------------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  **N - participants before exclusion**                                       3,219           11,478          2,084           12,174^*f*^     1,644           1,100           5,271           4,305
  **N - participants after exclusion with genome-wide genotypes available**   2,471           6,486           1,769           7,636^*f*^      1,427           927             3,710           4,091
   Sex, Men, n (%)                                                            922 (37.3)      2,977 (45.9)    773 (43.7)      3,511 (46.0)    728 (51.0)      447 (48.2)      1,541 (39.8)    1,782 (43.5)
   Age, years, mean                                                           76.1 ± 5.4      53.9 ± 5.7      72.9 ± 5.4      39.9 ± 10.3     61.6 ± 9.9      56.2 ± 7.1      67.8 ± 8.5      42.5 ± 17.1
   PR interval, ms, mean                                                      171.4 ± 27.7    162.7 ± 23.7    167.9 ± 28.5    152.1 ± 21.9    163.3 ± 23.3    164.6 ± 21.2    165.9 ± 24.1    154.2 ± 26.7
   RR interval, ms, mean ± SD                                                 925.9 ± 156.5   915.7 ± 132.4   949.1 ± 155.5   905.7 ± 174.8   963.5 ± 160.6   930.7 ± 139.2   861.9 ± 137.4   921.2 ± 152.2
   BMI, kg/m2, mean ± SD                                                      27.1 ± 4.4      26.7 ± 4.7      26.5 ± 4.5      26.1 ± 4.9      28.0 ± 4.4      27.8 ± 4.5      26.1 ± 3.5      25.2 ± 4.6
   Height, cm, mean ± SD                                                      166.4 ± 9.1     168.8 ± 9.4     164.9 ± 9.6     169.1 ± 9.5     167.1 ± 9.1     167.4 ± 8.8     167.3 ± 9.3     160.1 ±8.9
   Systolic BP, mmHg, mean ± SD                                               143 ± 20        117.2 ± 16.3    137 ± 21        120 ± 15        134 ± 20        132 ± 19        139 ± 22        125 ± 18
   Beta-Blockers (%)                                                          780 (31.6)      Excluded        176 (10.0)      Excluded        283 (19.8)      99 (10.7)       Excluded        Excluded
   Diuretics (%)                                                              733 (29.7)      562 (8.7)       434 (24.5)      ND              273 (19.1)      76 (8.2)        292 (7.5)       45 (1.1)
   Calcium Antagonists\* (%)                                                  131 (5.3)       Excluded        78 (4.4)        Excluded        ND              ND              Excluded        Excluded
   SD of PR residual after adjustment for covariates, ms                      25.9            23.0            26.9            20.5            21.3            20.1            23.0            25.5

###### 

Genome-wide significant association findings for PR interval obtained at nine independent loci. In each locus at least one marker exceeds the genome-wide significant threshold of *P*\<5 × 10^-8^. Betas estimate the difference in PR interval per one additional copy of the minor allele, adjusted for the covariates in the model. Column "Method" indicates whether a SNP was directly genotyped on one of the array platforms (G) or whether its genotype was imputed in all of the samples (I). The RSQR and the MAF are averages weighted by study size. RSQR (sometimes also termed OEvar) denotes the average of the observed by expected variance ratio of any SNP which indicates deviation from Hardy-Weinberg equilibrium and quality of imputation. All these SNPs met QC criteria in each study as outlined in [Supplementary Tables 2 and 3](#SD1){ref-type="supplementary-material"}. Effect size (beta) is reported in milliseconds (ms) per one copy of the minor allele. We observed no heterogeneity in effect size estimates between studies and report the I^2^-statistic results as the ratio of between-study to overall variance in betas.

  Locus         SNP          chr   Position (build 36)   Gene related position   minor/major allele   Meth od   RSQR (OEvar)   Freq coded (minor) allele   beta (ms)   SE (ms)   Association -P value   Heterogenei ty -- I^2^ statistic   Heterogenei ty -- P value
  ------------- ------------ ----- --------------------- ----------------------- -------------------- --------- -------------- --------------------------- ----------- --------- ---------------------- ---------------------------------- ---------------------------
  *MEIS1*       rs11897119   2     66,625,504            Intron 8                C/T                  G         1.008          0.389                       1.3624      0.207     4.62 × 10^-11^         0                                  0.803
  *SCN5A*       rs11708996   3     38,608,927            Intron 14               C/G                  I         0.927          0.149                       3.0403      0.2886    6.00 × 10^-26^         0.045                              0.396
  *SCN10A*      rs6800541    3     38,749,836            Intron 14               C/T                  G         0.995          0.404                       3.7687      0.2065    2.10 × 10^-74^         0.490                              0.056
  *ARHGAP24*    rs7692808    4     86,860,173            Intron 2                A/G                  I         0.984          0.306                       -2.0146     0.2203    5.99 × 10^-20^         0                                  0.711
  *NKX2-5*      rs251253     5     172,412,942           3kb 5′ of C5orf41       C/T                  G         0.971          0.399                       -1.4924     0.2091    9.45 × 10^-13^         0                                  0.926
  *CAV1/CAV2*   rs3807989    7     115,973,477           Intron 2 of CAV1        A/G                  G         0.970          0.395                       2.2959      0.2086    3.66 × 10^-28^         0                                  0.626
  *WNT11*       rs4944092    11    75,587,267            Intron 1                G/A                  G         1.006          0.321                       -1.1916     0.2155    3.22 × 10^-08^         0                                  0.549
  *SOX5*        rs11047543   12    24,679,606            51 kb 5′ of C12orf67    A/G                  I         0.983          0.147                       -2.0907     0.2872    3.34 × 10^-13^         0                                  0.912
  *TBX5/TBX3*   rs1896312    12    113,830,807           226 kb 5′ of TBX3       C/T                  I         0.936          0.279                       1.9505      0.2311    3.13 × 10^-17^         0                                  0.768

###### 

Characteristics of participants included in the meta-analysis of the association of the nine significant PR loci with atrial fibrillation. Overall the CHARGE prevalent AF sample included 896 cases, the CHARGE incident AF sample included 2,517 cases and the case-control sample included 2,328 cases ^a^The n given is the number of participants in the CHARGE cohorts and the number of cases plus controls in case control studies, ^b^Age was defined as age at DNA collection. BMI: body mass index; NA: age at onset of prevalent AF not available for CHS and RS.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baseline Characteristics     CHARGE studies: Prevalent AF Analysis   CHARGE studies: Incident AF Analysis   Case Control Studies: Prevalent AF Analysis                                                                                                
  ---------------------------- --------------------------------------- -------------------------------------- --------------------------------------------- ------------ ------------ ------------ ------------ ------------- ------------ ------------- -------------
  **Participants**                                                                                                                                                                                                                                       

  n^a^                         2,959                                   3,267                                  4,464                                         5,974        2,718        8,086        3,201        4,184         5,665        6,218         347

  Sex, men, n\                 1,154\                                  1,278\                                 2,004\                                        2,427\       1,011\       3,814\       1,241\       1,830\        2,282\       3,569\        202\
  (%)                          (39.0)                                  (39.1)                                 (44.9)                                        (40.6)       (37.2)       (47.2)       (38.8)       (43.7)        (40.3)       (57.4)        (58.2)

  Age^b^, years, mean (SD)     76.5 (5.5)                              72.3 (5.4)                             65.5 (12.7)                                   69.4 (9.1)   76.3 (5.5)   57.0 (5.7)   72.2 (5.3)   64.7 (12.6)   69.1 (9.0)   52.7 (14.0)   56.4 (8.2)

  Age^b^, years, min-max       66-95                                   65-98                                  30-100                                        55-99        66-95        46-70        65-98        30-100        55-99        14-93         20-88

  Hypertension, n\             2,260\                                  1,711\                                 2,263\                                        1,997\       2,145\       2192\        1,677\       2,062\        1,866\       1,902\        151\
  (%)                          (79.8)                                  (52.4)                                 (50.8)                                        (33.4)       (78.9)       (27.1)       (52.4)       (49.4)        (32.9)       (30.6)        (43.5)

  **Cases**                                                                                                                                                                                                                                              

  Atriial fibrillarion cases   241                                     66                                     280                                           309          138          731          763          343           542          2,145         183

  Age at AF onset, mean (SD)   76.9 (6.0)                              NA                                     70.6 (10.6)                                   NA           80.6 (6.0)   67.0 (6.7)   81.2 (6.0)   77.4 (10.5)   77.7 (7.7)   59.7 (11.2)   46.0 (11.0)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Meta-analytic results for the association of the nine significant PR loci with atrial fibrillation. Meta-analyzed were results from a meta-analysis of prevalent AF conducted in the CHARGE cohorts, results from a meta-analysis of incident AF conducted in the CHARGE cohorts, results from the AFNET case-control study and results from the CCAF case-control study. The Bonferroni adjusted table-wide significance threshold is *P*= 0.05/9= 5.6E-03, the p(adjusted) column reports the significance thresholds after adjustment for 9 tests. For all five SNPs we identified as associated with AF the minor allele decreased the risk of AF irrespective of the direction of its effect on PR interval.

  Nearest gene   SNP          Chr   pos build36   PR prolonging allele   Frequency -- PR prolonging allele   OR for AF -- PR prolonging Allele   OR for AF -- 95% CI lower bound   OR for AF -- 95% CI upper bound   P (unadjusted)   P (adjusted)   Effect of PR prolonging allele towards AF risk   Effect of minor allele towards AF risk
  -------------- ------------ ----- ------------- ---------------------- ----------------------------------- ----------------------------------- --------------------------------- --------------------------------- ---------------- -------------- ------------------------------------------------ ----------------------------------------
  *MEIS1*        rs11897119   2     66,625,504    C                      0.39                                1.01                                0.97                              1.06                              0.65             \-             ns                                               ns
  *SCN5A*        rs11708996   3     38,608,927    C                      0.15                                **0.90**                            **0.84**                          **0.96**                          **7.0E-04**      **6.30E-03**   **Decreased**                                    **Decreased**
  *SCN10A*       rs6800541    3     38,749,836    C                      0.40                                **0.92**                            **0.88**                          **0.96**                          **1.5E-04**      **1.35E-03**   **Decreased**                                    **Decreased**
  *ARHGAP24*     rs7692808    4     86,860,173    G\*                    0.69                                1.01                                0.97                              1.06                              0.56             \-             ns                                               ns
  *NKX2-5*       rs251253     5     172,412,942   T\*                    0.61                                **1.07**                            **1.03**                          **1.12**                          **2.3E-03**      **2.07E-02**   **Increased**                                    **Decreased**
  *CAV1/CAV2*    rs3807989    7     115,973,477   A                      0.40                                **0.91**                            **0.87**                          **0.95**                          **2.2E-05**      **1.98E-04**   **Decreased**                                    **Decreased**
  *WNT11*        rs4944092    11    75,587,267    A\*                    0.67                                0.94                                0.90                              0.99                              0.01             \-             ns                                               ns
  *SOX5*         rs11047543   12    24,679,606    G\*                    0.85                                **1.13**                            **1.06**                          **1.20**                          **2.1E-04**      **1.89E-03**   **Increased**                                    **Decreased**
  *TBX5/TBX3*    rs1896312    12    113,830,807   C                      0.30                                0.99                                0.95                              1.04                              0.72             \-             ns.                                              ns.
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